Compare CNK & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | TWST |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2007 | 2018 |
| Metric | CNK | TWST |
|---|---|---|
| Price | $25.48 | $43.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $32.90 | ★ $48.75 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 05-18-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $3,115,000,000.00 | $376,572,000.00 |
| Revenue This Year | $10.82 | $18.89 |
| Revenue Next Year | $3.68 | $15.28 |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | 2.15 | ★ 20.32 |
| 52 Week Low | $21.60 | $23.30 |
| 52 Week High | $34.01 | $57.88 |
| Indicator | CNK | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 42.10 |
| Support Level | $24.84 | $42.89 |
| Resistance Level | $25.50 | $45.76 |
| Average True Range (ATR) | 0.90 | 2.63 |
| MACD | -0.28 | -0.83 |
| Stochastic Oscillator | 2.25 | 6.34 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.